SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-329638"
 

Search: onr:"swepub:oai:DiVA.org:uu-329638" > Oncolytic alphaviru...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Martikainen, MiikaUppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för immunologi, genetik och patologi,Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, Kuopio 70211, Finland (author)

Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017-05-30
  • NATURE PUBLISHING GROUP,2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-329638
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-329638URI
  • https://doi.org/10.1038/bjc.2017.151DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Despite recent therapeutic and diagnostic advances, prostate cancer remains the second leading cause of cancer-related deaths among men in the Western world. Oncolytic viruses that replicate selectively in tumour cells represent a novel treatment candidate for these malignancies.Methods: We analysed infectivity of avirulent Semliki Firest virus SFV-VA7 in human prostate cancer cell lines VCaP, LNCaP and 22Rv1 and in nonmalignant prostate epithelial cell line RWPE-1. Therapeutic potency of SFV-VA7 was evaluated in subcutaneous and orthotopic mouse LNCaP xenograft models.Results: SFV-VA7 infected and killed the tested human prostate cancer cell lines irrespective of their hormone response status, while the nonmalignant prostate epithelial cell line RWPE-1 proved highly virus resistant. Notably, a single peritoneal dose of SFV-VA7 was sufficient to eradicate all subcutaneous and orthotopic LNCaP tumours.Conclusions: Our results indicate that SFV-VA7 is a novel, promising therapeutic virus against prostate cancer warranting further testing in early clinical trials.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ruotsalainen, JanneUniv Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, Kuopio 70211, Finland.;Univ Hosp Magdeburg, Dept Dermatol, D-39120 Magdeburg, Germany. (author)
  • Tuomela, JohannaUniv Turku, Inst Biomed, FIN-20520 Turku, Finland. (author)
  • Harkonen, PirkkoUniv Turku, Inst Biomed, FIN-20520 Turku, Finland. (author)
  • Essand, MagnusUppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för immunologi, genetik och patologi(Swepub:uu)magnessa (author)
  • Heikkila, JariAbo Akad Univ, Dept Biochem & Pharm, Turku 20500, Finland. (author)
  • Hinkkanen, AriUniv Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, Kuopio 70211, Finland. (author)
  • Uppsala universitetScience for Life Laboratory, SciLifeLab (creator_code:org_t)

Related titles

  • In:British Journal of Cancer: NATURE PUBLISHING GROUP117:1, s. 51-550007-09201532-1827

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view